We’re thrilled to announce a significant milestone in the realm of orthopedic care: AposHealth®’s groundbreaking research has been accepted for publication in the esteemed Journal of Novel Physiotherapies. This research sheds light on the long-term efficacy of Apos®—a flagship product of AposHealth® —in managing hip osteoarthritis (OA), offering tangible results of surgery avoidance and pain reduction for patients struggling with this debilitating condition.
The study focused on evaluating the clinical impact of Apos® among NHS patients with hip OA who had not responded to core therapies and were potential candidates for joint replacement surgery. What makes this research particularly noteworthy is that it’s the first of its kind to provide long-term evidence specifically targeting patients with hip OA.
Key findings include:
- Surgery Avoidance: Over 80% of the patients managed to avoid hip replacement surgery for at least three years—a remarkable achievement that underscores the effectiveness of Apos® in preventing the need for invasive procedures.
- Pain Reduction and Improved Function: The findings also demonstrated a significant reduction in pain, with over 40% of patients experiencing a noticeable improvement in their ability to carry out daily activities. This improvement in function is crucial for enhancing the quality of life for individuals grappling with hip OA.
- Enhanced Gait Velocity: Another encouraging outcome was the observed increase of 25% in gait velocity among the patients. This improvement not only signifies enhanced mobility but also suggests a positive impact on overall physical well-being.
These findings not only reinforce the extensive evidence supporting the efficacy of Apos® but also underscore its potential to revolutionize the management of hip OA. For those interested in delving deeper into the research, the full article can be accessed here.
About AposHealth®
At AposHealth®, we are passionate about revolutionizing the treatment of musculoskeletal conditions simply, by addressing peoples’ gait and pain – to help them move better and live better. Our flagship solution, Apos®, is FDA-cleared to temporarily reduce knee pain caused by osteoarthritis and has been used by over 130,000 patients. It can also be used as a general wellness device to help patients live well with chronic lower back and hip pain. With a 96% satisfaction rate,3 and over 69 peer-reviewed publications, this program—consisting of gait analysis, a personalized foot-worn device, and a customized treatment plan—has helped patients worldwide move, live, and thrive.
